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How malignant gliomas arise in a mature brain remains a mystery,
hindering the development of preventive and therapeutic inter-
ventions. We previously showed that oligodendrocyte precursor
cells (OPCs) can be transformed into glioma when mutations are
introduced perinatally. However, adult OPCs rarely proliferate com-
pared with their perinatal counterparts. Whether these relatively
quiescent cells have the potential to transform is unknown, which is
a critical question considering the late onset of human glioma.
Additionally, the premalignant events taking place between initial
mutation and a fully developed tumor mass are particularly poorly
understood in glioma. Here we used a temporally controllable Cre
transgene to delete p53 and NF1 specifically in adult OPCs and dem-
onstrated that these cells consistently give rise to malignant gliomas.
To investigate the transforming process of quiescent adult OPCs, we
then tracked these cells throughout the premalignant phase, which
revealed a dynamic multistep transformation, starting with rapid but
transient hyperproliferative reactivation, followed by a long period of
dormancy, and then final malignant transformation. Using pharmaco-
logical approaches, we discovered that mammalian target of rapamy-
cin signaling is critical for both the initial OPC reactivation step and
late-stage tumor cell proliferation and thusmight be a potential target
for both glioma prevention and treatment. In summary, our results
firmly establish the transformingpotential of adultOPCs and reveal an
actionable multiphasic reactivation process that turns slowly dividing
OPCs into malignant gliomas.
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The quiescence and reactivation of progenitor cells play es-sential roles in tissue homeostasis, regeneration, and cancer
(1–5). As tissues mature, progenitor cells often enter a quiescent
state characterized by greatly reduced proliferation relative to
embryonic levels, although they can be transiently reactivated
into high levels of proliferation by physiologic stimuli or signals
for tissue repair. Although most progenitors become increasingly
quiescent with aging (6–9), cancer incidence is highest in seniors,
suggesting a critical role of cellular reactivation for tumorigenesis.
Because not all cell types can be equally activated (10–13), iden-
tifying the cell of origin for adult cancers and understanding the
mechanisms of their reactivation should provide critical insights
for cancer prevention and treatment.
Malignant gliomas are devastating, incurable brain tumors, and
particularly little is known about the early stages of their de-
velopment. Recently, we showed that perinatal oligodendrocyte
precursor cells (OPCs) can give rise to glioma upon the loss of p53
and neurofibromatosis 1 (NF1) (14), two of the most frequently
mutated tumor suppressor genes in human glioblastoma (GBM)
(15, 16). However, the transforming potential of perinatal OPCs
could result from a synergy between genetic lesions and the rapid
proliferation of OPCs at this age. Compared with their perinatal
counterparts, adult OPCs are relatively quiescent (9, 17–19). Al-
though all adult OPCs retain the ability to proliferate, they do so at
a very slow rate, dividing only once in 36 d at P60 (60-d-old mice)
compared with every 4 d at P6 (9, 19). Furthermore, adult OPCs
adopt a transcriptional program with much decreased expression of
cell cycle genes (20, 21), thus contributing to their infrequent
proliferation. Reactivation of adult quiescent OPCs has been
previously characterized in response to neuronal activity and to
brain injury, both of which trigger proliferation followed by dif-
ferentiation into myelinating oligodendrocytes (22–24), but never
in the context of oncogenic mutations. Because 87% of human
malignant gliomas occur after 55 y of age (25), it is necessary to
investigate whether adult OPCs can be transformed into tumors,
and if so, how they become reactivated. Mechanisms regulating
progenitor cell quiescence are beginning to emerge (1, 26),
including the mammalian target of rapamycin (mTOR) path-
way, which has known functions in normal OPC biology (27–
30). If adult OPCs can form gliomas, such pathways might play
important roles in the tumorigenic process.
Here we focused on adult high-grade gliomas rather than
pediatric gliomas, which are molecularly and clinically distinct
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(31, 32). Therefore, we inactivated p53 and NF1 specifically in
adult OPCs and found that these cells consistently give rise to
malignant gliomas. Interestingly, we found that gliomagenesis from
adult OPCs is not a simple linear process. Upon mutation, OPCs
become immediately reactivated, reaching the proliferative rate of
perinatal OPCs. Rather than continue to proliferate, mutant OPCs
return to a dormancy state, until eventually one or a few cells es-
cape dormancy for a second time, and malignant transformation
ensues in specific brain regions. Knowledge of this process could
yield novel opportunities to halt the progression of gliomagenesis.
To exploit that possibility, we tested the role of mTOR signaling
and found that it is critical for both initial OPC reactivation and
later-stage tumor cell proliferation, making this pathway a good
candidate for both glioma therapy and prevention.
Results
Establishing a Model to Examine the Transforming Potential of Adult
OPCs. To determine whether adult OPCs can be transformed into
gliomas, we established a model that contains (i) an NG2-CreER
transgene to excise floxed alleles specifically in OPCs in a tamoxi-
fen (Tmx)-dependent fashion (33), (ii) floxed alleles of p53 and
NF1 (p53KO/flox,NF1flox/flox), two of the most frequently mutated tu-
mor suppressor genes in human glioma (15), and (iii) a Cre-
inducible reporter gene, ROSA26-LSL-tdTomato (tdT), to identify
recombined cells (Fig. 1A). We will refer to mice with homozygous
conditional p53 and NF1 mutations as conditional KOs (CKOs)
and to their controls (no p53 or NF1mutations) as WT. To induce
mutations specifically in adults, we administered Tmx at either 45
or 180 d of age (young or aged adults).
To ensure that our model targets mutations to OPCs in the
adult, we first confirmed the temporal and cell type specificity of
the NG2-CreER transgene. To test the temporal specificity of
NG2-CreER, we analyzed the brains of adult mice not given Tmx
and found very few tdT+ cells, whereas 5 d of Tmx yielded many
labeled cells (Fig. S1A), indicating that CreER activity is highly
dependent on Tmx administration. Labeled cells were distributed
evenly throughout the brain, with slightly fewer in the cerebellum
(Fig. 1B), consistent with the known distribution of OPCs in the
adult brain (34). These results suggest that our approach targets
OPCs without spatial bias. To test the cell type specificity of NG2-
CreER, we characterized all tdT+ cells 1 d after a 5-d Tmx
treatment (5 dpi). The majority of tdT+ cells are platelet-derived
growth factor (PDGF) receptor α (PDGFRα)+ OPCs (72.1 ±
1.4% SEM in olfactory bulb, n= 3mice; Fig. 1C). Other tdT+ cells
are mostly PDGFRβ+ pericytes (Fig. S1B), a nonneural cell type
known to express NG2, as well as some CC1+ oligodendrocytes
(Fig. S1C), which likely differentiated from labeled OPCs. No
tdT+ astrocytes were detected (Fig. 1D). Although rare, tdT+
cortical pyramidal neurons were also found (Fig. S1D); their la-
beling likely indicates a low level of NG2-CreER transgene expres-
sion directly in mature neurons (33) because our experimental
timing is too short and too late for cortical neurogenesis to occur.
We conclude that our mouse model effectively targets mutations to
adult OPCs without spatial bias.
Fig. 1. Glioma mouse model using inducible NG2-
CreER to specifically mutate adult OPCs. (A) Before
tamoxifen (Tmx) administration, all cells are p53
heterozygous (p53KO/flox), NF1 WT (NF1flox/flox), and
colorless because CreER is sequestered in the cyto-
plasm. To induce mutations in floxed p53 and NF1
alleles and expression of the tdTomato (tdT) re-
porter transgene, Tmx was given for 5 d, starting at
P45 or P180, causing CreER protein in NG2+ cells to
enter the nucleus. Mice were then killed at different
dpi depending on the experimental purpose. (B)
Sagittal sections of mouse WT whole brain given 5 d
Tmx at P45 and killed 1 d later, showing that
recombination (tdT+ cells) is evenly distributed
throughout all brain regions. (C and D) Immuno-
histochemical characterization of tdT+ cells showing
that recombination occurs in OPCs (PDGFRα+, Olig2+)
(C) but not in astrocytes (Aldolase-C+, GFAP+) (D).
(Scale bars, 40 μm.)












NG2-CreER Does Not Target Adult Neural Stem Cells. Although our
data above reinforced the reliability of our mouse model, to un-
ambiguously determine the transformation potential of adult OPCs,
it is particularly important to ensure that NG2-CreER does not label
adult neural stem cells (NSCs), which are known to give rise to gli-
oma upon oncogenic mutations (35). To address this question, we
first characterized tdT+ cells in the subventricular zone (SVZ), the
largest stem cell niche in the adult brain. The SVZ contains GFAP+
(glial fibrillary acidic protein) NSCs (type B cells), which generate
Ascl1+ transient amplifying cells (type C cells) that differentiate into
PSA-NCAM+ neuroblasts (36) (type A cells; Fig. 2A). We found no
tdT+ cells within the SVZ that could be identified as typeB (GFAP+),
type C (Ascl1+/PDGFRα−), or type A (PSA-NCAM+/Olig2−)
cells (Fig. 2 B–E), strongly suggesting that SVZ NSCs are not
labeled by NG2-CreER. In a complementary experiment, we
analyzed the olfactory bulb (OB), the final destination of SVZ
NSC-derived neuroblasts, for signs of adult-generated neurons
derived from tdT+ NSCs (Fig. S2). We administered BrdU
(5-bromo-2′-deoxyuridine) to adult WT mice to label newly gen-
erated cells (Fig. S2E) and stained for BrdU and NeuN (Neu-
ronal Nuclei, neuron marker) at 51 dpi (Fig. S2 C and D), when
all NSC-derived neurons would have migrated to the OB and
matured (37, 38). If NG2-CreER mediates recombination in
NSCs, we would expect to see a population of newly formed tdT+
OB neurons (tdT+/BrdU+/NeuN+). Although we found many new
neurons (BrdU+/NeuN+), none of them were tdT+, suggesting that
NG2-CreER does not induce recombination in SVZ NSCs. Based
on both SVZ and OB analyses, we conclude that NG2-CreER does
not induce recombination in SVZ NSCs.
Adult OPCs Generate Malignant Gliomas upon p53/NF1 Mutation.
Having confirmed the reliability of our mouse model, we next
Fig. 2. NG2-CreER does not target adult SVZ neural stem cells. (A) Diagrams illustrating the cell types in the SVZ and oligodendrocyte lineages and the molecular
markers used to identify them. (B–D) WTmice were given Tmx for 5 d at P45 and then killed 2 d (6 dpi; B), 3 d (7 dpi; C), or 7 d (11 dpi; D) later, allowing sufficient
time for each cell type to be labeled or generated (85). Brains were then immunostained to detect tdT+ cells expressing markers of type B (GFAP, B), type C (Ascl1,
C), or type A cells (PSA-NCAM, D) in the SVZ. DAPI nuclear staining (omitted for simplicity) was used to define the boundaries of the cell-dense SVZ (dotted lines).
PDGFRα, expressed by OPCs but not C cells, was used to distinguish these cell types (both can be Ascl1+). Olig2, expressed by OPCs but not A cells, was used to
distinguish these cell types (both can be PSA-NCAM+). (E) Quantification results, showing that tdT+ cells in the SVZ are either in the oligodendrocyte lineage or
likely pericytes (PDGFRβ+), but not part of the SVZ stem cell lineage (n = 4 mice for type A cells, n = 3 mice for others). (Scale bars, 50 μm.)
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tested if adult OPCs can give rise to gliomas. We induced p53/
NF1 loss of function mutations at two different adult ages (P45
and P180) using the 5-d Tmx administration scheme. In both
cases, CKO mice developed tdT+ masses in the brain with 100%
penetrance between 120 and 200 dpi, with the exception of one
early tumor at 62 dpi (Fig. 3A), whereas untreated control mice
never did (Table S1), confirming the adult onset of our glioma
mouse model. Cells in tdT+ masses are actively proliferating
(Fig. 3C and Fig. S3E) and H&E staining showed that all masses
manifest typical features of malignant anaplastic glioma, in-
cluding high cellularity, mitotic figures, apoptotic cells, in-
vasiveness, and cellular and nuclear atypia (Fig. 3D). Although
NG2-CreER can also introduce mutations into pericytes, no his-
topathological features of hemangio-pericytoma were detected,
making it unlikely that these tumors are derived from pericytes. It
should also be noted that these tumors are likely astrocytomas and
Fig. 3. Adult OPCs consistently give rise to malignant proneural gliomas in defined brain regions. (A) Tmx-treated mice developed brain tumors between 120 and 200
dpi in all but one case (62 dpi, P180 induction), regardless of the age of induction (P45, n = 15 mice, or P180, n = 11 mice). (B) Tumors were found in a few defined
regions, as illustrated on diagrams of sagittal (Upper) and coronal (Lower) sections. These regions include the olfactory bulb (OB), habenula (Hab), bottom of the brain
(BoB), and the area spanning the piriform cortex and amygdala (Cx/Amy). Dotted lines mark the cross sections from which the coronal diagrams are derived. (C)
Examples of early- (120 dpi) and late-stage (180 dpi) tumors in the brain regions illustrated in the diagrams. Early-stage tumors are shown on sagittal sections and late-
stage tumors on coronal sections. All tumors contained many actively dividing (Ki67+) cells (Insets, taken from area marked by asterisk in 180 dpi examples). Quan-
tification of tumor locations (table) was performed at 120 dpi and showed that the OB is the most common location (n = 20 tumors in 11 brains). (D) H&E staining of
section containing tumor in the Cx/Amy, showing multiple features of anaplastic, malignant gliomas, such as high cellularity, invasiveness, mitotic figures (M), apoptotic
cells (A), and nuclear and cellular atypias (Ak/Ac) (n = 6 tumors). (Inset) Tumor location (dotted line) in coronal hemisection; asterisk marks location of highmagnification
image. (E) Transcriptome comparison (ssGSEA) between tumor samples and the four subtypes of human glioblastoma (GBM) reveals similarity between OPC-derived
gliomas and human proneural GBM subtype. Glioma samples were also compared with gene expression signatures of five neuroglial cell types (Oligo: oligodendrocyte),
showing that all OPC-derived gliomas are most similar to OPCs, consistent with their cellular origin (NSC-Cre: Neural Stem Cell-Cre, includes two Nestin-Cre and one
hGFAP-Cre samples; NSC-Cre and NG2-Cre ssGSEA data were previously published (14) and are provided here for comparison). [Scale bars, (C) 1 mm and (D) 20 μm.]












not oligodendrogliomas based on the presence of angular, pleo-
morphic, rather than rounded, isomorphic nuclei and the lack of
perinuclear halos or branched capillaries (Fig. 3D) (39, 40). The
engraftment of tumor cells into the brains of NOD/SCID mice
consistently gave rise to large, invasive secondary and tertiary tumors
after 35–50 d (Table S1), confirming the malignancy of OPC-
derived gliomas. Additionally, tumor cells cultured in clonal
conditions exhibited self-renewing and multilineage differentia-
tion potential (Fig. S3 A–D), suggesting the existence of tumor-
propagating cells within adult OPC-derived gliomas. Therefore,
we conclude that even relatively quiescent OPCs in a fully ma-
ture brain can give rise to glioma.
Interestingly, we noticed that tumors were not randomly dis-
tributed, despite equal distribution of mutant OPCs in all brain
regions (Fig. 1B). Because it is difficult to pinpoint the anatomical
origin of late-stage tumors due to their large size and infiltrative
nature, we collected a set of brains at 120 dpi, when tumors are
small, to quantify tumor frequency at distinct locations. The most
common location was the OB (40%), followed by the habenula, a
small region in the dorsal thalamus (25%), piriform cortex/amyg-
dala (15%), and the space between the hypothalamus and the base
of the skull (15%) (Fig. 3 B and C and Table S1). Altogether, we
conclude that OPCs in the adult brain can exit their quiescent state
and give rise to malignant anaplastic gliomas upon p53/NF1 deletion.
Adult-Induced Gliomas Are Similar to Human Proneural Glioma and
Maintain OPC Features. Recent studies have used genomic and
transcriptomic approaches to define glioma subtypes within
Fig. 4. Reactivation of mutant OPCs
upon NG2-CreER–mediated mutagene-
sis. (A and B) Representative images of
OB sagittal sections from 12 dpi WT (A)
and CKO (B) mice immunostained for
the reporter gene (tdT), an OPC marker
(PDGFRα), and a proliferation marker
(BrdU). (C) Quantification of the fraction
of proliferating tdT+ OPCs in the OB at
various time points starting before Tmx
was administered (0 dpi), as well as
12, 50, and 90 dpi, revealing a transient
spike in mutant OPC proliferation at 12
dpi (for 0 dpi, proliferation was quanti-
fied among all PDGFRα+ cells; no tdT+
cells). Dashed line, proliferation level of
perinatal (P6) OPCs (n = 4). (D) Quanti-
fication in the OB of the total number of
tdT+ OPCs starting before Tmx was ad-
ministered (0 dpi), as well as 12, 50, and
90 dpi, showing that mutant OPCs ac-
cumulate throughout the premalignant
phase, even after the proliferative rate
returns to basal level (n = 4). (E) Location
of images shown in A and B and diagram
of experimental procedure. (F and G)
Representative images of OB sagittal
sections from 90 dpi WT (F) and CKO (G)
mice immunostained for an OPC marker
(PDGFRα) and a mature oligodendrocyte
marker (CC1) (white arrows, tdT+/
PDGFRα+ cells; blue arrows, tdT+/CC1+
cells). (H) Quantification of the percent-
age of tdT+/PDGFRα+ (OPCs), tdT+/CC1+
(oligodendrocytes), or tdT+/PDGFRα+/CC1+
cells in the OB of WT and CKO mice at
90 dpi, suggesting mutant OPCs cannot
differentiate effectively (n = 4 CKO and
3 WT mice). (I) Location of images shown
in F and G and diagram of experimental
procedure. Error bars represent SEM and
statistical significance was determined
by Student t test (*P < 0.05; **P < 0.01;
***P < 0.001). (Scale bars, 50 μm.)
E4218 | www.pnas.org/cgi/doi/10.1073/pnas.1414389111 Galvao et al.
pathologically indistinguishable tumor samples (41–46). These
molecular classifications provide valuable insight for prognostic
predictions and development of targeted therapies and emphasize
the importance of matching distinct mouse glioma models to
human subtypes. Therefore, we used microarray data to compare
the transcriptional profile of 12 adult OPC-derived gliomas to that
of human GBM samples by single sample Gene Set Enrichment
Analysis (ssGSEA), which uses predefined sets of genes to de-
termine the relative similarity between samples (Fig. 3E). The
gliomas selected for analysis were large, terminal tumors that
sometimes spanned several brain regions but likely originated in
the OB (tumors 1, 3, 7, and 8), thalamus (tumor 10), piriform
cortex/amygdala (tumors 2, 4, 5, and 9), and base of the skull (tumor
6), as well as two secondary tumors grafted from the OB and cortex/
amygdala into the striatum (tumors 11 and 12, respectively; Table
S1). We found that, regardless of anatomical origin or age of in-
duction, most tumors from our model resemble the proneural
subtype of human GBM (46), although some could not be un-
ambiguously identified as proneural or classical (tumors 5–8; Fig.
3E). Consistent with their proneural signature, our adult-induced
gliomas were similar to OPCs, but not neurons or astrocytes (Fig.
3E and Fig. S3 E–I) (46). Markers of pericytes and hemangio-
pericytomas (47) were also absent from these gliomas, consistent
with their OPC origin (Fig. S3I). Interestingly, although many
GFAP+ cells were detected within the tumor masses, these were
not tdT+ (Fig. S3H), indicating that they are most likely local re-
active astrocytes. These data concur with our previous findings
with neonatal OPC-derived tumors (14) (Fig. 3E), suggesting that
gliomas originated from p53/NF1-null OPCs generally belong to
the proneural subtype regardless of the timing of mutations.
Adult OPC Gliomagenesis Follows a Multistep Process of Reactivation,
Dormancy, and Malignancy. Having confirmed the transformation
capability of adult OPCs, we next investigated how these rarely
dividing progenitors become reactivated. To pinpoint the timing
of OPC reactivation, we quantified both proliferative rate and total
number of OPCs at several time points during the premalignant
phase (preceding a detectable tumor). We initially focused on the
OB, where gliomas most commonly develop in our model (Fig. 4
A–E). Before Tmx is given (0 dpi), WT and CKOOPCs have equally
low proliferative rates. Just 12 d after Tmx (12 dpi), the proliferative
rate ofmutantOPCs increased to perinatal levels (54.9± 3.6%SEM;
n = 3), but then quickly decreased to below WT levels at 50 dpi and
remained low even at 90 dpi, just 30 d before gliomas begin to appear
(Fig. 4C). As a consequence of reactivation, the number of tdT+
mutant OPCs rose sharply in the first 12 d after Tmx administra-
tion. Surprisingly, the number of mutant OPCs continued to ex-
pand long after cells returned to WT proliferation levels (Fig. 4D),
likely due to defects in differentiation of mutant OPCs (see below).
In contrast, the number of labeled WT OPCs remained constant
(Fig. 4D). Interestingly, we observed similar proliferation and cell
number dynamics not only in other tumor hot spots (habenula), but
also in regions where gliomas did not normally form (cingulate/
motor cortex and corpus callosum; Fig. S4 A–F) except pro-
liferation in the corpus callosum, which was identical in WT and
CKOmice. Overall, these results suggest that additional events are
needed for malignant transformation.
Fig. 5. mTOR signaling is necessary for mutant OPC reactivation. (A and B) Immunostaining of the OB of CKO mice treated with vehicle or temsirolimus,
showing that the levels of phospho-S6 (pS6, mTOR downstream target) are drastically reduced by the drug. (C) Western blot for pS6 and total S6 protein in
the OB, showing temsirolimus blocks phosphorylation of S6 by mTOR. Mice were treated for 10 (A and B) or 5 (C) d and then killed 4 h after the last dose. (D)
Diagrams of experimental procedure and brain region analyzed (red arrow). (E) Quantification of the fraction of proliferating tdT+ OPCs at 12 dpi in the OB
of CKO mice treated with vehicle (Veh, control) or temsirolimus (Tem). Tem significantly decreases mutant OPC proliferation to WT adult OPC proliferation
levels (dotted line) (Veh, n = 3; Tem, n = 4; **P < 0.01). (Scale bar, 100 μm.)












In addition to proliferation, the differentiation of OPCs into
mature oligodendrocytes also affects their homeostatic balance. To
determinewhether p53/NF1mutations perturbOPCdifferentiation,
we quantified the percentage of tdT+ cells expressing PDGFRα
(OPCs) or CC1 (oligodendrocytes) in theOB ofWT andCKOmice
at 90 dpi (Fig. 4 F–I). Compared with WT mice, CKO mice had
significantly more tdT+/PDGFRα+ cells and significantly fewer
tdT+/CC1+ cells, indicating an impairment in OPC differentiation.
As with proliferation, impaired differentiation was observed in all
regions tested (Fig. S4G), including the corpus callosum, which
could explain the increase in OPC numbers despite a lack of
hyperproliferation in that region. Therefore, compromised dif-
ferentiation of mutant OPCs, together with the early spike in
proliferation, likely contributes to their continuous expansion
throughout the premalignant phase, eventually leading to gli-
oma. Importantly, OPCs mutated at P180 exhibited the same
hyperproliferative (49% vs. 20% BrdU+, P < 0.01) and un-
differentiated (88% vs. 72% PDGFRα+, P < 0.01) behaviors at
12 dpi (n = 3), indicating that OPC reactivation competence is
not lost over time. In summary, we found that gliomagenesis
from adult OPCs involves multiple steps of cellular behavior
alternations, including robust but transient reactivation in all
brain regions immediately after mutagenesis, followed by slow but
steady mutant cell expansion during a long period of apparent
dormancy, and ending with sudden malignant transformation.
mTOR Inhibition Blocks Mutant OPC Reactivation Step. To study the
molecular nature of the reactivation step, we focused on the
mTOR signaling pathway, which has recently emerged as a key
mechanism in the reactivation of quiescent neural, hematopoi-
etic, and muscle stem cells (48–51) and is known to play a role
in OPC proliferation and differentiation (27–30, 52). Therefore,
we decided to test its involvement in mutation-induced OPC
reactivation by administering the mTOR inhibitor temsirolimus
throughout the 12 dpi period. The effectiveness of target inhibition
in the brain was confirmed by immunostaining and Western blot
(Fig. 5 A–C), both of which showed that brains of mice treated
with temsirolimus have drastically reduced levels of phosphory-
lated S6 ribosomal protein (pS6), a downstream target of mTOR.
Quantification of proliferation showed that OPCs in CKO mice
treated with temsirolimus no longer underwent the characteristic
12 dpi spike, but instead remained at WT levels (Fig. 5E). Total
OPC numbers were also reduced by mTOR inhibition (Fig. S5).
These results suggest that mTOR signaling is necessary for the
early reactivation of mutant OPCs.
mTOR Signaling Rises Dramatically in Malignant OPCs and Is Critical
for Glioma Cell Proliferation. As our data above implicate mTOR
signaling in the initial reactivation step of the premalignant
phase, we next investigated whether this pathway is necessary at
the malignant phase as well. We first quantified the percentage of
pS6+ OPCs at premalignant and malignant stages. We found that
most pS6+ cells in the adult OB are neurons (Fig. S6A), and that,
unexpectedly, only 2% of OPCs are pS6+ in WT or CKO mice at
12 dpi (Fig. 6B and Fig. S6 B and C), perhaps due to low levels of
mTOR signaling (Discussion). In stark contrast, the percentage of
pS6+ OPCs increased drastically to 20% in the tumor mass (Fig. 6 A
and B). We observed the same trend when staining for the phos-
phorylated form of another mTOR downstream target, 4E-binding
protein 1 (4E-BP1), which was rarely seen before malignancy but
quite common in tumor cells (Fig. S6D). Therefore, mTOR sig-
naling appears to be highly up-regulated in malignant OPCs.
To test the role of mTOR signaling in OPC-derived glioma cells,
we cultured cells from one of our primary gliomas with temsir-
olimus. Tumor cell growth was acutely sensitive to this mTOR
inhibitor at doses that inhibited S6 and 4E-BP1 phosphorylation
(Fig. 6D and Fig. S6F). Cell cycle analysis by flow cytometry dem-
onstrated that this effect was due to cell cycle arrest at the G1 stage
(Fig. 6 E and F), consistent with the known roles of mTOR sig-
naling in promoting cell cycle progression at the G1 to S transition
(53). These results were confirmed with EdU (5-ethynyl-2′-deoxy-
uridine) quantifications by immunostaining, as well as using
another mTOR inhibitor (rapamycin, from which temsirolimus
is derived) and another primary glioma cell line (Fig. S6G–I). We
conclude that OPC-derived glioma cells greatly increase cell in-
trinsic mTOR signaling, which is important for their proliferation.
Fig. 6. mTOR signaling rises dramatically in malignant
OPCs and is critical for glioma cell proliferation. (A) Immu-
nostaining for phospho-S6 (pS6, mTOR target) in glioma
tissue. (B) Quantification of the percentage of OPCs (tdT+/
PDGFRα+) and OPC-derived glioma cells (tdT+ cells in tumor
mass, typically all PDGFRα+ as seen on Fig. S6D; adjacent
section of tumor in A and Fig. S3F) labeled with pS6, in-
dicating higher levels of mTOR signaling in glioma cells (n = 3;
**P < 0.01). (C) Diagrams of location of image shown in A and
experimental procedure. (D) Cellular viability assay of cultured
glioma cells treated with temsirolimus, revealing a significant
impact of this mTOR inhibitor on glioma cell growth in vitro.
(E) Quantification of the fraction of glioma cells at different
phases of the cell cycle (G0/G1, S, G2/M) and apoptosis (sub-
G1) after exposure to increasing doses of temsirolimus,
showing an increase in G0/G1 and decrease in G2/M that
suggests G1 arrest. (F) DNA content distribution of untreated
and temsirolimus-treated tumor cells, illustrating the drug-
induced cell cycle arrest at G1 (jagged black line, actual data
curve; smooth black line, fitted data curve; colored areas,
cells presumed to be in different cell cycle stages, as per color
code). (Scale bar, 100 μm.)
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Discussion
A deep understanding of the timing and process of gliomagenesis
should greatly facilitate the development of effective therapies
and biomarkers for early detection. We developed a genetic
mouse model with both cell type specificity and temporal control
to study gliomagenesis from adult OPCs for the first time. Using
this model, we showed that quiescent adult OPCs can be reac-
tivated upon mutagenesis and transform into malignant gliomas
that preferentially develop in defined locations. Time course
analysis revealed a surprising, multistep behavior of mutant OPC
reactivation, dormancy, and malignant transformation. Finally, we
uncovered an important role for mTOR signaling at both early and
late stages of gliomagenesis.
Although previous studies have suggested NSCs as the cell of
origin for glioma (35, 54, 55), our prior work showed that even
though introducing mutations in NSCs can lead to glioma, ma-
lignant transformation only occurs in OPCs, thus warranting a
distinction between cell of mutation (NSCs) and cell of origin
(OPCs) (14). It remains possible that additional cell types also act
as a cell of origin, such as the OPC-like type C* cells described by
others (56), or that different glioma subtypes are derived from
different cells of origin, such as low-grade ocular tract gliomas,
which might not be OPC-derived (57). Nonetheless, overwhelming
evidence now supports OPCs as a cell of origin for glioma (14, 58–
64). However, these studies either introduced oncogenes into OPCs
early in development, as in our previous work (14), or did not use
lineage tracing tools (58, 59). Thus, it is possible that the glioma-
genic potential of OPCs could be dependent on their active peri-
natal state (65, 66) and that adult OPCs may not be transformable
because they rarely divide (9, 17–21). Our current study convinc-
ingly resolved this issue by introducing mutations specifically into
adult OPCs and demonstrating their capacity for transformation.
Because most human malignant gliomas occur in elderly adults
(25), our findings not only firmly establish OPCs as a cell of origin
for glioma but also highlight the clinical relevance of this discovery.
Because gliomas have no known morphologically detectable
preneoplastic lesions, it is difficult to study early events before final
malignancy. Taking advantage of the lineage marker tdTomato in
our mouse model, we followed the progression of gliomagenesis
and found that it is not a linear process but rather marked by
successive steps of reactivation, dormancy, and malignant trans-
formation. The reactivation step is likely caused by signaling per-
turbations due to the acute loss of p53 and NF1, but mutant OPCs
quickly return to quiescence/dormancy. This dormancy could be
due to cell intrinsic tumor suppressor mechanisms activated by NF1
loss of function (67) or cell extrinsic mechanisms including com-
petition for limited trophic support or cell contact-mediated
growth inhibition as the number of mutant OPCs increases (68).
Interestingly, mutant OPCs continue to accumulate throughout
this dormant period, likely due to an inability to differentiate into
oligodendrocytes. This lack of differentiation distinguishes
mutation-induced from physiological or injury-induced OPC
reactivation, which is a controlled process ending with differen-
tiation of the reactivated cells (22–24). Eventually, one or more
mutant cells exit dormancy to undergo malignant transformation,
triggering the formation of a tumor mass. The mechanism for
malignant transformation remains unclear, but likely depends on
additional mutations that allowOPCs to overcome the barriers that
kept them dormant after the initial reactivation. Overall, the dis-
covery of a stepwise process of gliomagenesis providesmultiple new
potential therapeutic approaches, such as early interventions to
prevent OPC reactivation or to induce their differentiation, which
might help prevent gliomagenesis by halting the progression toward
malignant transformation.
The malignant transformation step could also be dependent
on niche properties of certain brain regions, as suggested by our
finding that malignant gliomas develop preferentially in specific
locations. In fact, regional differences in the expression of sig-
naling molecules have been suggested to account for the unique
properties of CNS progenitors in those areas as well as their re-
sponse to oncogenic mutations (12, 13, 69, 70). Alternatively, OPCs
themselves could have heterogeneous characteristics depending on
the brain region (52, 71, 72), which could influence their trans-
formation potential. Future studies investigating these possibilities
might provide critical insights into what drives gliomagenesis.
The mTOR pathway has recently emerged as a key mechanism
in stem cell reactivation. In Drosophila, nutrient-stimulated
TOR signaling reactivates quiescent neural stem cells during the
embryo-to-larva transition (51). In mammals, adult hematopoietic
stem cells are kept quiescent via TSC1-mediated inhibition of
mTOR (48, 49), and quiescent adult muscle stem cells display an
mTOR-dependent increase in proliferation and cell size after in-
jury (50). In OPCs, mTOR signaling promotes proliferation and
differentiation during development (27–30, 52), and its activity is
blocked by p53 via stress-induced up-regulation of mTOR inhib-
itors (73) and NF1 via Ras inhibition (74, 75). Therefore, mTOR
could be part of the molecular mechanism behind mutation-
induced adult OPC reactivation. Consistent with its role in de-
velopment, we found that pharmacological inhibition of mTOR
signaling with temsirolimus decreased WT adult OPC proliferation
(22.6% vs. 5.8% BrdU+, P = 0.004) and differentiation (55.6% vs.
65.6% PDGFRα+, P = 0.01). Importantly, temsirolimus treatment
also blocked mutant OPC hyperproliferation at 12 dpi, indicating
that this pathway is necessary for the initial reactivation step. In-
terestingly, temsirolimus did not affect mutant OPC differentiation,
likely because this process was already impaired by the loss of p53
and NF1. Because the mTOR pathway is also active in a variety of
cancers (76), we investigated its role in malignant OPC proliferation
and found that blocking mTOR strongly inhibits tumor cell growth.
Overall, our results show thatmTOR signaling is involved in both the
initial reactivation of p53/NF1-mutant OPCs as well as the un-
controlled proliferation of OPC-derived gliomas. These findings
should provide the rationale and facilitate the regimen design for
an effective use of the next generation of mTOR inhibitors cur-
rently being developed (76). Specifically, treatment early in the
course of disease could be beneficial and could prevent low- to
high-grade glioma progression. Due to the complex mutational
landscape of malignant gliomas (15, 16), such treatments would
likely be most effective as part of a combinatorial strategy in which
multiple deregulated pathways would be targeted.
Given the clear effect of the mTOR inhibitor temsirolimus in
blockingOPC proliferation at 12 dpi, we were surprised to find that
very few OPCs at this time point have detectable levels of pS6 or
p4E-BP1, both downstream targets of mTOR and common indi-
cators of pathway activity. This lack of pS6 or p4E-BP1 signals
could be due to mTOR signaling occurring below detection levels
in these cells, which could be necessary to avoid cellular senescence
and/or apoptosis, as reported for Kras and Myc oncogene sig-
naling (77–81). Alternatively, mTOR signaling in premalignant
OPCs could occur through untested downstream targets or
temsirolimus could exert its antiproliferative effect via mTOR-in-
dependent mechanisms (82, 83). One intriguing possibility is that
mTOR signaling in pS6+ cells in the brain could have a paracrine
effect on OPCs, as occurs in nutrient-dependent reactivation of
quiescent Drosophila neural stem cells (51). Nevertheless, once
mutant OPCs become malignant, mTOR’s proliferative role is likely
cell autonomous based on their robust labeling with pS6 and p4E-
BP1 in vivo and their sensitivity to temsirolimus in vitro. Although its
exact mode of action warrants further investigation, temsirolimus
prevents both mutant OPC reactivation and tumor cell pro-
liferation, pinpointing mTOR signaling as an integral part of the
gliomagenic process.
In summary, our results have solidified the role of OPCs as a
cell of origin for glioma and shed light on the poorly understood
premalignant phase of gliomagenesis. Our findings have also led












to important questions. How do mutant OPCs become dormant
after the initial reactivation? What causes their eventual escape
from the dormant state to form a tumor? What mechanisms are
responsible for tumor hot spots? The answers to these questions
will continue to advance our understanding of glioma and will
hopefully bring us closer to effective treatments.
Materials and Methods
Additional details are available in SI Materials and Methods.
In Vivo Drug Delivery. All mice were given daily tamoxifen doses of 200 mg/kg
for several consecutive days (2 d for perinatal mice, 5 d for adult mice, except
mice used for dosage curve, Fig. S1A; and mice used for detection of new OB
neurons, Fig. S2). BrdU was given by i.p. (adult mice) or s.c. (perinatal mice)
injection at 50 mg/kg. Mice were given one injection per day for 7 d and
killed 24 h after the last injection. Temsirolimus (CCI-779; Selleckchem) was
injected i.p. at 100 mg/kg (40 μL/g body weight) daily for 10 d. Mice were
killed 4 h after the last dose was delivered.
Tumor Cell Grafting. CKO mice suspected of having a primary brain tumor
were decapitated to dissect the tumor mass, which was then dissociated to a
single cell suspension; 105 cells were immediately grafted into the striatum
of each NOD-SCID mouse.
Sphere-Forming Assay. Cultured tumor cells were plated onto nonadhering
96-well plates and 60-mm dishes at clonal density (100 cells/μL, 104 cells/well
for 96-well plates, 5 × 105 cells/dish for 60-mm dishes) in medium supple-
mented with EGF (20 ng/mL) and FGF2 (10 ng/mL). To differentiate, spheres
were placed on matrigel-coated plates in medium without EGF/FGF2 and
with 1% FBS for 6 d.
Microarray Analysis and Single Sample Gene Set Enrichment Analysis. 44K
Mouse Development OligoMicroarrays from Agilent Technologies were used
to analyze total RNA extracted from bulk tumor tissue that was hybridized
against a common reference sample of RNA pooled from four WT P17 mouse
brain neocortices. Single sample GSEA was performed as described elsewhere
(46). To compare tumor samples to the different mouse brain cell types, data
from a previous publication (84) was downloaded and preprocessed as de-
scribed previously (46) into sets of 250 variably expressed gene clusters. The
clusters used in the present study contained postnatal day 16 myelin oligo-
dendrocytes (n = 4), postnatal day 6–7 OPCs (n = 2), postnatal day 7 neurons
(n = 4), and postnatal day 17–30 astrocytes (n = 6). Gene sets for four pre-
viously described GBM subtypes (46) were defined by selecting the top 250
marker genes as provided.
Cell Growth Assay. OPC-derived glioma cells were treated with increasing
concentrations of temsirolimus (Selleckchem), rapamycin (Sigma-Aldrich), or
DMSO (untreated). Growth of treated vs. untreated cells was determined at
5 d after treatment using CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (MTS; Promega). Cell growthwas determined in quadruplicate per drug
concentration and data pooled from two independent experiments.
Cell Cycle Analysis. OPC-derived glioma cells were treated with increasing
concentrations of temsirolimus, harvested 48 h later, and stained with the
Guava Cell Cycle Reagent (EMDMillipore), and DNA content was determined
using a Guava EasyCyte Plus flow cytometer. Data were obtained in triplicate
per drug concentration and data pooled from two independent experiments.
For quantification of proliferation by EdU incorporation, tumor cells were
cultured for 3 d in 100 nM temsirolimus and then given EdU for 8 h and
immediately fixed in 4% (wt/vol) formaldehyde.
Immunoblots. For in vivo experiments, OB tissue fromWTmice treated for 5 d
with vehicle or temsirolimus was collected 4 h after the last dose and im-
mediately flash-frozen in liquid nitrogen until further processing. For in vitro
experiments, OPC-derived glioma cells treatedwith temsirolimus for 24 hwere
harvested and lysed. For both types of experiments, protein concentrationwas
quantified using the BCA assay (BioRad), and immunoblots were performed by
resolving equal amounts of protein by gradient [8–16% (vol/vol)] SDS/PAGE
(Bio-Rad) and transferred to PVDF membranes (EMD Millipore) for
immunodetection.
Quantifications and Statistics. Cryosections (16 μm thick; or 30-μm-thick
vibratome sections for type A and C cell quantifications) were imaged with
a confocal microscope. The significance of the quantification data was cal-
culated by Student t test. All error bars represent SEM.
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